Citigroup Reiterates “Outperform” Rating for ConvaTec Group (LON:CTEC)

ConvaTec Group (LON:CTEC)‘s stock had its “outperform” rating reiterated by Citigroup in a report released on Thursday, MarketBeat Ratings reports. They currently have a GBX 315 target price on the stock. Citigroup’s target price points to a potential upside of 28.58% from the company’s previous close.

A number of other equities analysts have also weighed in on the company. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of ConvaTec Group in a research note on Friday, November 14th. Berenberg Bank upped their price objective on ConvaTec Group from GBX 330 to GBX 340 and gave the company a “buy” rating in a report on Thursday, January 22nd. UBS Group reissued a “buy” rating and set a GBX 375 target price on shares of ConvaTec Group in a report on Friday, November 7th. Finally, Peel Hunt restated an “add” rating and issued a GBX 270 price target on shares of ConvaTec Group in a research note on Thursday, November 13th. Seven analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of GBX 319.57.

ConvaTec Group Trading Down 1.5%

Shares of CTEC stock opened at GBX 244.99 on Thursday. ConvaTec Group has a 12-month low of GBX 209.40 and a 12-month high of GBX 311.20. The company has a market capitalization of £4.78 billion, a PE ratio of 23.11, a price-to-earnings-growth ratio of 0.93 and a beta of 0.76. The firm has a 50 day moving average price of GBX 235.99 and a two-hundred day moving average price of GBX 236.72. The company has a quick ratio of 0.96, a current ratio of 1.53 and a debt-to-equity ratio of 106.19.

ConvaTec Group Company Profile

ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.